AR and colorectal carcinoma: A further study showed that PTUPB was more effective than indomethacin and celecoxib in suppressing AKR1C3 activity and proliferation of CRPC cells, and the combination of PTUPB and enzalutamide provided benefits by blocking AR/AR-V7 signaling, thereby inhibiting the proliferation of castration relapsed VCaP xenografts and patient-derived CRC, organoids, and xenografts [71].